Thrombosis in pregnancy: Maternal and fetal issues

Lancet

Volumn 353, Issue 9160, 1999, Pages 1258-1265

  Greer, Ian A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

DEEP VEIN THROMBOSIS; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LUNG EMBOLISM; MATERNAL MORTALITY; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; THROMBOPHILIA; THROMBOSIS; UNITED KINGDOM;

EID: 0033541493     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10265-9     Document Type: Review

References (60)

1. Greer IA, de Swiet M. Thrombosis prophylaxis in obstetrics and gynaecology. Br J Ostet Gynaecol 1993; 100: 37-40.
2. Vincent T, Rai R, Regan L, Cohen H. Increased thrombin generation in women with recurrent miscarriage. Lancet 1998; 353: 116.
3. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-57.
4. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet (in press).
5. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scot Med J 1996; 41: 83-86.
6. Rutherford S, Montoro M, McGhee W, Strong T. Thromboembolic disease associated with pregnancy: an 11 year review. Am Obstet Gynecol 1991; 164 (suppl): 286.
7. McColl M, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thrombo embolism. Thromb Haemost 1997; 78: 1183-88.
8. Lindhagen A, Bergqvist A, Bergqvist D, Hallbook T. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. Br J Obstet Gynaecol 1986; 93: 348-52.
9. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-70.
10. Greer IA. Haemostasis and thrombosis in pregnancy. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1994: 987-1015.
11. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104: 191-97.
12. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
13. Walker ID. Congenital thrombophilia. In: Greer IA, ed. Bailliere's clinical obstetrics and gynaecology - thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 431-45.
14. Zoller B, Holm J, Dahlback B. Resistance to activated protein C due to factor V gene mutation: the most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996; 6: 45.
15. Bokarewa MI, Wramsby N, Bremme K, Blomback M. Variability of the response to activated protein C during normal pregnancy. Blood Coag Fibrinol 1997; 8: 239.
16. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the three untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 36-38.
17. McColl MD, Walker ID, Greer IA. A mutation in the prothrombin gene contributing to venous thrombosis in pregnancy. Br J Obstet Gynaecol 1998; 105: 923-25.
18. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1998; 334: 759-62.
19. Conard J, Horellou MH, van Dreden P, Le Compte T, Samama M. Thrombosis in pregnancy and congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-20.
20. de Stefano V, Leone G, Masterangela S, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of anti-thrombin III, protein C-protein S. Thromb Haemost 1994; 71: 799-800.
21. Hough RE, Makris N, Preston FR. Pregnancy in women with thrombophilia: incidence of thrombosis and pregnancy outcome. Br J Haematol 1996; 93 (suppl 2): 136 (abstr).
22. Pabinger I and the Study Group on Natural Inhibitors. Thrombotic risk in hereditary anti-thrombin III, protein C or protein S deficiency. Arter Thromb Vasc Biol 1996; 16: 742-48.
23. Hallak M, Senderowica J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated ith thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
24. Bokarewa MI, Bremme K, Blomback M. Arg 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-78.
25. de Stefano V, Leone G, Masterangelo S, et al. Thrombotic risk during pregnancy and puerperium in women with APC resistance: effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost 1995; 74: 793-94.
26. Rai RS, Regan L, Hadley E, Dave M, Cohen H. Second trimester pregnancy loss is associated with activated Protein C resistance. Br J Haematol 1996; 92: 489-90.
27. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent explained fetal losses. Thromb Haemostas 1997; 77: 822-24.
28. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551-54.
29. Dizon-Townson DS, Meline L, Nelson LM, Barner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177: 402-05.
30. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217-23.
31. Belasch J, Riverter JC, Fabregues F, et al. First trimester repeated abortion is not associated wtih activated protein C resistance. Hum Reprod 1997; 12: 1094-97.
32. Rai RS, Regan L, Chitolie A, Donald JG, Cohen H. Placental thrombosis in second trimester miscarriage in association with activated Protein C resistance. Br J Obstet Gynaecol 1996; 103: 842-44.
33. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-16.
34. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin, Protein S and Protein S deficient women. Thromb Haemost 1996; 75: 387-88.
35. Havercate F, Samama M. Familial dysfibrinogenaemia and thrombophilia - report on a study of the SSC sub-committee on fibrinogen. Thromb Haemostas 1995; 73: 151-61.
36. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early onset of pre-eclampsia. Am J Obstet Gynecol 1996; 173: 104-45.
37. De Vries JIP, Dekker J, Huijgens PC, Jakobs C, Blomberg BME, van Geijn HP. Hyperhomocysteinaemia and Protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104: 1248-54.
38. Rotmensch S, Liberati M, Mittlemann M, Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol 1997; 177: 170-73.
39. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe pre-eclampsia. Am J Obstet Gynaecol 1996; 175: 902-05.
40. Grandone E, Margagilione M, Colazzo D, et al. Factor V Leiden. C>TMTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Haemostas 1997; 77: 1052-54.
41. Leeda M, Riyazi N, de Vries JIP, Jakobs C, van Geijn HP, Dekker GA. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of pre-eclampsia or fetal growth restriction. Am J Obstet Gynecol 1998; 179: 136-39.
42. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Pre-eclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176: 457-60.
43. 506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
44. Kupferminc MJ, Amiram E, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 1: 9-13.
45. Macklon NS, Greer IA, Reid AW, Walker ID. Thrombocytopenia antithrombin deficiency and extensive thromboembolism in pregnancy - treatment with low molecular weight heparin. Blood Coag Fibrinol 1995; 6: 672-75.
46. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. In: Greer IA, ed. Bailliere's clinical obstetrics and gynaecology - thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 489-509.
47. Bates SM, Ginsberg JS. Anticoagulants in pregnancy: fetal defects. In: Greer IA, ed. Bailliere's clinical obstetrics and gynaecology -thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 479-88.
48. Warkentin TE, Levine MN, Hisch J, et al. Heparin induced thrombocytopenia in patients treated wtih low molecular weight heparin or unfractionated heparin. NEnglJ Med 1995; 332: 1330-35.
49. Letsky E. Peripartum prophylaxis of thromboembolism. In: Greer IA, ed. Bailliere's clinical obstetrics and gynaecology - thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 23-43.
50. Greer IA. Epidemiology, risk factors, and prophylaxis of venous thromboembolism in obstetrics and gynaecology. In: Greer IA, ed. Bailliere's clinical obstetrics and gynaecology - thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 403-30.
51. Macklon NS, Greer IA. Technical note: compression stockings and posture - a comparative study of their effects on the proximal deep veins in the leg at rest. Br J Radiol 1995; 68: 515-18.
52. Thrombombolic risk factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-74.
53. Macklon NS. Diagnosis of deep venous thrombosis and pulmonary embolism. In: Greer IA, eds. Bailliere's clinical obstetrics and gynaecology - thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 463-77.
54. Lowe GDO. Treatment of venous thrombo embolism. In: Greer IA, ed. Bailliere's clinical obstetrics and gynaecology - thromboembolic disease in obstetrics and gynaecology. London: Bailliere Tindall, 1997: 511-21.
55. Thomson AJ, Walker ID, Greer IA. Low molecular weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet 1998; 352: 1904.
56. Brennand JE, Walker ID, Greer IA. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with Enoxaparin. Acta Haematol 1999; 101: 53-55.
57. Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coag Fibrinol 1998; 9: 343-50.
58. Gibson JL, Ekevall K, Walker ID, Greer IA. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. Br J Obstet Gynaecol 1998; 105: 795-97.
59. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens and guidelines for regional anesthetic management. Anesth Analg 1997; 85: 874-85.
60. Report of the RCOG Working Party on Prophylaxis Against Thromboemolism in Gynaecology and Obstetrics. London: Royal College of Obstetricians and Gynaecologists, 1995.